Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging

(2009) A P Anandarajah et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

(2009) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

The clinical utility of inhibiting CD28-mediated costimulation

(2009) Peter S. Linsley et al.   IMMUNOLOGICAL REVIEWS

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

(2009) MA Radtke et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

(2008) A W R van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment recommendations for psoriatic arthritis

(2008) C T Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study

(2008) Philip J. Mease et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

(2008) Nicolino Ruperto et al.   LANCET

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

(2007) H K Genant et al.   ANNALS OF THE RHEUMATIC DISEASES